Approvals issued in July, August, and September 2023 included a new treatment for prostate cancer harboring BRCA mutations, two new bispecific T-cell engagers for multiple myeloma, a special kit to treat liver metastases from uveal melanoma, and more.
The FDA approved a kit that allows for liver-directed delivery of the chemotherapy melphalan to treat metastatic liver disease from uveal melanoma. The U.S. Food and Drug Administration (FDA) has approved a kit for...
The FDA has approved another T-cell engager therapy for patients with heavily pretreated multiple myeloma The U.S. Food and Drug Administration (FDA) has granted accelerated approval to elranatamab-bcmm (Elrexfio) for the treatment of adult...
The FDA approved a combination of the PARP inhibitor niraparib with a hormone therapy agent for certain patients with metastatic prostate cancer The U.S. Food and Drug Administration (FDA) has approved the combination of...
The FDA granted full approval to pralsetinib as a treatment for certain patients with non-small cell lung cancer The U.S. Food and Drug Administration has granted full approval to pralsetinib (Gavreto) to treat adult...
Certain patients with advanced multiple myeloma may be eligible for treatment with a new immunotherapy drug. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to talquetamab-tgvs (Talvey) for patients with multiple...
The FDA approved a combination of trifluridine, tipiracil, and bevacizumab for the treatment of heavily pretreated metastatic colorectal cancer. The U.S. Food and Drug Administration (FDA) has approved trifluridine and tipiracil (Lonsurf), in combination...
The FDA has approved an immune checkpoint inhibitor in combination with chemotherapy to treat certain adult patients with endometrial cancer The U.S. Food and Drug Administration (FDA) has approved dostarlimab-gxly (Jemperli) in combination with...
The FDA has approved an inhibitor of FLT3 for use across multiple phases of acute myeloid leukemia treatment. The U.S. Food and Drug Administration (FDA) has approved quizartinib (Vanflyta) for the treatment of patients...
New oral hormonal therapy offers alternative to injections for some women with metastatic disease.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn MoreYour donation to the American Association for Cancer Research helps our more than 54,000 members worldwide drive progress against cancer.
Donate Now